In many ways, 2023 has been a transformational year where we made significant progress on our Novo Nordisk Pharmatech growth strategy. Our revenue grew significantly to 880 MDKK in net sales and landed 47% higher than 2022 reflecting a good year across all products, and on top of that, we have brought three new products into our pipeline.
